Strongyloides hyperinfection syndrome: an emerging global infectious disease

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 4, 2008, Pages 314-318

  Marcos, Luis A ^a,b   Terashima, Angelica ^b   DuPont, Herbert L ^a,c,d,e   Gotuzzo, Eduardo ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d St Luke's Episcopal Hospital   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Emerging diseases; Hyperinfection; Review; Strongyloides stercoralis; Strongyloidiasis

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; IVERMECTIN; TIABENDAZOLE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CADAVER DONOR; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DEVELOPED COUNTRY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIARRHEA; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMORAL IMMUNITY; HYPERINFECTION SYNDROME; IMMIGRATION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; INFECTION RISK; LYMPHOMA; MALNUTRITION; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PREVALENCE; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TH2 CELL; TRAVEL; TUBERCULOSIS;

ANIMALS; ANTHELMINTICS; COMMUNICABLE DISEASES, EMERGING; HUMANS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SUPERINFECTION; SYNDROME;

HUMAN T-LYMPHOTROPIC VIRUS 1; STRONGYLOIDES; STRONGYLOIDES STERCORALIS;

EID: 40249086494     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.01.020     Document Type: Review

References (40)

1. Barker E., Mackewicz C.E., and Levy J.A. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc. Natl. Acad. Sci. USA 92 (1995) 11135-11139
2. Barrett K.E., Neva F.A., Gam A.A., Cicmanec J., London W.T., Phillips J.M., and Metcalfe D.D. The immune response to nematode parasites: modulation of mast cell numbers and function during Strongyloides stercoralis infections in nonhuman primates. Am. J. Trop. Med. Hyg. 38 (1988) 574-581
3. Boulware D.R., Stauffer W.M., Hendel-Paterson B.R., Rocha J.L., Seet R.C., Summer A.P., Nield L.S., Supparatpinyo K., Chaiwarith R., and Walker P.F. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am. J. Med. 120 (2007) 545-551
4. Brown M., Cartledge J.D., and Miller R.F. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int. J. STD AIDS 17 (2006) 560-561
5. Carvalho E.M., and Da Fonseca P.A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 26 (2004) 487-497
6. Celedon J.C., Mathur-Wagh U., Fox J., Garcia R., and Wiest P.M. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus: a report of 3 cases and review of the literature. Medicine (Baltimore) 73 (1994) 256-263
7. Centers for Disease Control (CDC), 1987. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb. Mortal. Wkly. Rep. 36, 1-15.
8. Cimerman S., Cimerman B., and Lewi D.S. Enteric parasites and AIDS. Sao Paulo Med. J. 117 (1999) 266-273
9. Concha R., Harrington Jr. W., and Rogers A.I. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J. Clin. Gastroenterol. 39 (2005) 203-211
10. Corrigan C.J. Cellular effects of glucocorticoids. Immunol. Allergy Clin. North Am. 19 (1999) 671-682
11. Culshaw R.J., Bancroft G.J., and McDonald V. Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma interferon production. Infect. Immun. 65 (1997) 3074-3079
12. Davidson R.A., Fletcher R.H., and Chapman L.E. Risk factors for strongyloidiasis. A case-control study. Arch. Intern. Med. 144 (1984) 321-324
13. DeVault Jr. G.A., King J.W., Rohr M.S., Landreneau M.D., Brown III S.T., and McDonald J.C. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev. Infect. Dis. 12 (1990) 653-671
14. Fardet L., Généreau T., Cabane J., and Kettaneh A. Severe strongyloidiasis in corticosteroid-treated patients. Clin. Microbiol. Infect. 12 (2006) 945-947
15. Genta R.M. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev. Infect. Dis. 11 (1989) 755-767
16. Genta R.M., Miles P., and Fields K. Opportunistic Strongyloides stercoralis infection in lymphoma patients: report of a case and review of the literature. Cancer 63 (1989) 1407-1411
17. Herrera J., Marcos L., Terashima A., Alvarez H., Samalvides F., and Gotuzzo E. Factors associated with Strongyloides stercoralis infection in an endemic area in Peru. Rev. Gastroenterol. Peru 26 (2006) 357-362
18. Hirata T., Uchima N., Kishimoto K., Zaha O., Kinjo N., Hokama A., Sakugawa H., Kinjo F., and Fujita J. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am. J. Trop. Med. Hyg. 74 (2006) 246-249
19. Link K., and Orenstein R. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South. Med. J. 92 (1999) 728-731
20. Marcos L.A., Terashima A., Samalvides F., Alvarez H., Lindo F., Tello R., Canales M., Demarini J., and Gotuzzo E. Thiabendazole for the control of Strongyloides stercoralis infection in a hyperendemic area in Peru. Rev. Gastroenterol. Peru 25 (2005) 341-348
21. Marty F.M., Lowry C.M., Rodriguez M., Milner D.A., Pieciak W.S., Sinha A., Fleckenstein L., and Baden L.R. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin. Infect. Dis. 41 (2005) 5-8
22. Morgan J.S., Schaffner W., and Stone W.J. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation 42 (1986) 518-524
23. Neva F.A. Biology and immunology of human strongyloidiasis. J. Infect. Dis. 153 (1986) 397-406
24. Nuesch R., Zimmerli L., Stockli R., Gyr N., and Christoph F.R. Imported strongyloidosis: a longitudinal analysis of 31 cases. J. Travel Med. 12 (2005) 80-84
25. Nucci M., Portugal R., Pulcheri W., Spector N., Ferreira S.B., De Castro M.B., Noe R., and De Oliveira H.P. Strongyloidiasis in patients with hematologic malignancies. Clin. Infect. Dis. 21 (1995) 675-677
26. Oude Lashof A., Lesterhuis W.J., Wanten G., Beckers P., and Keuter M. Colitis in an alcohol-dependent woman. Lancet 369 (2007) 2050
27. Pacanowski J., Santos M.D., Roux A., Maignan C., Guillot J., Lavarde V., and Cornet M. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am. J. Trop. Med. Hyg. 73 (2005) 122-124
28. Page W.A., Dempsey K., and McCarthy J.S. Utility of serological follow-up of chronic strongyloidiasis after anthelminthic chemotherapy. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 1056-1062
29. Palau L.A., and Pankey G.A. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am. J. Trop. Med. Hyg. 57 (1997) 413-415
30. Petithory J.C., and Derouin F. AIDS and strongyloidiasis in Africa. Lancet 1 (1987) 921
31. Rodrigues R.M., De Oliveira M.C., Sopelete M.C., Silva D.A., Campos D.M., Taketomi E.A., and Costa-Cruz J.M. IgG1, IgG4, and IgE antibody responses in human strongyloidiasis by ELISA using Strongyloides ratti saline extract as heterologous antigen. Parasitol. Res. 101 (2007) 1209-1214
32. Said T., Nampoory M.R., Nair M.P., Halim M.A., Shetty S.A., Kumar A.V., Mokadas E., Elsayed A., Johny K.V., Samhan M., and Al-Mousawi M. Hyperinfection strongyloidiasis: an anticipated outbreak in kidney transplant recipients in Kuwait. Transplant. Proc. 39 (2007) 1014-1015
33. Satoh M., Toma H., Sato Y., Takara M., Shiroma Y., Kiyuna S., and Hirayama K. Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1. Clin. Exp. Immunol. 127 (2002) 354-359
34. Siddiqui A.A., and Berk S.L. Diagnosis of Strongyloides stercoralis infection. Clin. Infect. Dis. 33 (2001) 1040-1047
35. Tanaka M., Hirabayashi Y., Gatanaga H., Aizawa S., Hachiya A., Takahashi Y., Tashiro E., Kohsaka T., Oyamada M., Ida S., and Oka S. Reduction in interleukin-2-producing cells but not Th1 to Th2 shift in moderate and advanced stages of human immunodeficiency virus type-1-infection: direct analysis of intracellular cytokine concentrations in CD4+ CD8- T cells. Scand. J. Immunol. 50 (1999) 550-554
36. Terashima A., Alvarez H., Tello R., Infante R., Freedman D.O., and Gotuzzo E. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int. J. Infect. Dis. 6 (2002) 28-30
37. Vadlamudi R.S., Chi D.S., and Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin. Mol. Allergy 30 (2006) 4-8
38. Valdez H., and Lederman M.M. Cytokines and cytokine therapies in HIV infection. AIDS Clin. Rev. 98 (1997) 187-228
39. Van Doorn H.R., Koelewijn R., Hofwegen H., Gilis H., Wetsteyn J.C., Wismans P.J., Sarfati C., Vervoort T., and Van Gool T. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J. Clin. Microbiol. 45 (2007) 438-442
40. Verdonck K., González E., Van Dooren S., Vandamme A.M., Vanham G., and Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect. Dis. 7 (2007) 266-281